These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9512220)

  • 1. The origin of serum progesterone during the follicular phase of menotropin-stimulated cycles.
    Eldar-Geva T; Margalioth EJ; Brooks B; Algur N; Zylber-Haran E; Diamant YZ
    Hum Reprod; 1998 Jan; 13(1):9-14. PubMed ID: 9512220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between prolactin, gonadotrophins and steroid hormones in serum and follicular fluid after stimulation with gonadotrophin-releasing hormone agonists and human menopausal gonadotrophin for an in-vitro fertilization programme.
    Kamel MA; Zabel G; Bernart W; Neulen J; Breckwoldt M
    Hum Reprod; 1994 Oct; 9(10):1803-6. PubMed ID: 7844206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gonadotrophin stimulation for in vitro fertilization significantly alters the hormone milieu in follicular fluid: a comparative study between natural cycle IVF and conventional IVF.
    von Wolff M; Kollmann Z; Flück CE; Stute P; Marti U; Weiss B; Bersinger NA
    Hum Reprod; 2014 May; 29(5):1049-57. PubMed ID: 24608520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Follicular and luteal phase characteristics following early cessation of gonadotrophin-releasing hormone agonist during ovarian stimulation for in-vitro fertilization.
    Beckers NG; Laven JS; Eijkemans MJ; Fauser BC
    Hum Reprod; 2000 Jan; 15(1):43-9. PubMed ID: 10611186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
    Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
    Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure and highly purified follicle-stimulating hormone alone or in combination with human menopausal gonadotrophin for ovarian stimulation after pituitary suppression in in-vitro fertilization.
    Balasch J; Fábregues F; Creus M; Moreno V; Puerto B; Peñarrubia J; Carmona F; Vanrell JA
    Hum Reprod; 1996 Nov; 11(11):2400-4. PubMed ID: 8981119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction.
    Yding Andersen C; Westergaard LG; Figenschau Y; Bertheussen K; Forsdahl F
    Hum Reprod; 1993 Jun; 8(6):840-3. PubMed ID: 8345072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin.
    Harada T; Yoshida S; Katagiri C; Takao N; Ikenari T; Toda T; Mio Y; Terakawa N
    Hum Reprod; 1995 May; 10(5):1060-4. PubMed ID: 7657741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human follicle stimulating hormone versus human menopausal gonadotrophin induction: effects in mature follicle endocrinology.
    Teissier MP; Chable H; Paulhac S; Aubard Y
    Hum Reprod; 1999 Sep; 14(9):2236-41. PubMed ID: 10469686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovulation induction in clomiphene-resistant anovulatory women: differential follicular response to purified urinary follicle-stimulating hormone (FSH) versus purified urinary FSH and luteinizing hormone.
    Hoffman DI; Lobo RA; Campeau JD; Tsai HM; Holmberg EA; Ono T; Frederick JJ; Platt LD; diZerega GS
    J Clin Endocrinol Metab; 1985 May; 60(5):922-7. PubMed ID: 3920235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early follicular rise of serum progesterone concentration in response to a flare-up effect of gonadotrophin-releasing hormone agonist impairs follicular recruitment for in-vitro fertilization.
    Sims JA; Seltman HJ; Muasher SJ
    Hum Reprod; 1994 Feb; 9(2):235-40. PubMed ID: 8027278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The empty follicle syndrome: a pharmaceutical industry syndrome.
    Zegers-Hochschild F; Fernández E; Mackenna A; Fabres C; Altieri E; Lopez T
    Hum Reprod; 1995 Sep; 10(9):2262-5. PubMed ID: 8530648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human chorionic gonadotrophin and steroid concentrations in follicular fluid: the relationship to oocyte maturity and fertilization rates in stimulated and natural in-vitro fertilization cycles.
    Enien WM; el Sahwy S; Harris CP; Seif MW; Elstein M
    Hum Reprod; 1995 Nov; 10(11):2840-4. PubMed ID: 8747029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.
    Smitz J; Andersen AN; Devroey P; Arce JC;
    Hum Reprod; 2007 Mar; 22(3):676-87. PubMed ID: 17110397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human chorionic gonadotrophin is a better luteal support than progesterone in ultrashort gonadotrophin-releasing hormone agonist/menotrophin in-vitro fertilization cycles.
    Golan A; Herman A; Soffer Y; Bukovsky I; Caspi E; Ron-El R
    Hum Reprod; 1993 Sep; 8(9):1372-5. PubMed ID: 8253920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.